首页|肝细胞癌复发进程中DNA修复调节的蛋白质组学分析及验证

肝细胞癌复发进程中DNA修复调节的蛋白质组学分析及验证

扫码查看
目的 分析肝细胞癌(HCC)复发进程中DNA修复调节的作用及机制.方法 串联质量标签(TMT)标记的定量蛋白质组学方法分析HCC 2年内复发和5年预后良好的肝癌组织样本,分析富集在DNA复制、错配修复、碱基切除修复、核苷酸切除修复4条通路的蛋白表达差异,分析在HCC复发进程中起主要作用的调控通路及靶点,预测可能的调控机制.计量资料2组间比较采用成组t检验;多组间比较采用单因素方差分析,进一步两两比较采用LSD-t检验.结果 真核生物复制复合体通路MCM2(P=0.018)、MCM3(P=0.047)、MCM4(P=0.014)、MCM5(P=0.008)、MCM6(P=0.006)、MCM7(P=0.007)、PCNA(P=0.019)、RFC4(P=0.002)、RFC5(P<0.001)、LIG1(P=0.042)蛋白表达均显著降低;核苷酸切除修复通路中PCNA(P=0.019)、RFC4(P=0.002)、RFC5(P<0.001)、LIG1(P=0.042)共4个蛋白表达水平均显著减少;碱基切除修复通路PCNA(P=0.019)和LIG1(P=0.042)在HCC复发组中均显著降低;错配修复富集通路中MSH2(P=0.026)、MSH6(P=0.006)、RFC4(P=0.002)、RFC5(P<0.001)、PCNA(P=0.019)、LIG1(P=0.042)共6个蛋白在肝癌复发组织中均显著减少.差异蛋白涉及MCM复合体、DNA聚合酶复合体ε、连接酶LIG1、长补丁碱基剪切修复复合体(long patch BER)、DNA错配修复蛋白复合体的重要组分.对DNA修复调节的重要差异蛋白进行临床样本验证分析,结果表明复发组中除MCM6表现出下降趋势外,MCM5(P=0.008)、MCM7(P=0.007)、RCF4(P=0.002)、RCF5(P<0.001)和MSH6(P=0.006)蛋白相对表达量均显著降低.结论 HCC复发过程中,DNA修复进程中多个复合体蛋白组分存在显著减少或缺失.
Proteomic analysis and validation of DNA repair regulation in the process of hepatocellular carcinoma recurrence
Objective To investigate the role and mechanism of DNA repair regulation in the process of hepatocellular carcinoma(HCC)recurrence.Methods HCC tissue samples were collected from the patients with recurrence within two years or the patients with a good prognosis after 5 years,and the Tandem Mass Tag-labeled quantification proteomic study was used to analyze the differentially expressed proteins enriched in the four pathways of DNA replication,mismatch repair,base excision repair,and nucleotide excision repair,and the regulatory pathways and targets that play a key role in the process of HCC recurrence were analyzed to predict the possible regulatory mechanisms.The independent samples t-test was used for comparison of continuous data between two groups;a one-way analysis of variance was used for comparison between multiple groups,and the least significant difference t-test was used for further comparison between two groups.Results For the eukaryotic replication complex pathway,there were significant reductions in the protein expression levels of MCM2(P=0.018),MCM3(P=0.047),MCM4(P=0.014),MCM5(P=0.008),MCM6(P=0.006),MCM7(P=0.007),PCNA(P=0.019),RFC4(P=0.002),RFC5(P<0.001),and LIG1(P=0.042);for the nucleotide excision repair pathway,there were significant reductions in the protein expression levels of PCNA(P=0.019),RFC4(P=0.002),RFC5(P<0.001),and LIG1(P=0.042);for the base excision repair pathway,there were significant reductions in the protein expression levels of PCNA(P=0.019)and LIG1(P=0.042)in the HCC recurrence group;for the mismatch repair pathway,there were significant reductions in the protein expression levels of MSH2(P=0.026),MSH6(P= 0.006),RFC4(P=0.002),RFC5(P<0.001),PCNA(P=0.019),and LIG1(P=0.042)in recurrent HCC tissue.The differentially expressed proteins were involved in the important components of MCM complex,DNA polymerase complex,ligase LIG1,long patch base shear repair complex(long patch BER),and DNA mismatch repair protein complex.The clinical sample validation analysis of important differentially expressed proteins regulated by DNA repair showed that except for MCM6 with a trend of reduction,the recurrence group also had significant reductions in the relative protein expression levels of MCM5(P=0.008),MCM7(P=0.007),RCF4(P=0.002),RCF5(P<0.001),and MSH6(P=0.006).Conclusion There are significant reductions or deletions of multiple complex protein components in the process of DNA repair during HCC recurrence.

Carcinoma,HepatocellularNeoplasm Recurrence,LocalDNA RepairProteomics

常凯、王艳艳、江忠勇、孙巍、刘晨霞、那琬琳、许宏宣、谢静、刘媛、陈敏

展开 >

中国人民解放军西部战区总医院检验科, 成都 610083

成都市第七人民医院检验科, 成都医学院附属肿瘤医院, 成都 610041

四川省疾病预防控制中心微生物检验所, 成都 610041

成都市实验外国语学校生物教学与研究组, 成都 611134

西南大学药学院/中医药学院, 重庆 400715

展开 >

癌,肝细胞 肿瘤复发,局部 DNA修复 蛋白质组学

四川省自然科学基金四川省中医药管理局专项课题西部战区总医院应用基础研究项目西部战区总医院应用基础研究项目西部战区总医院星火青年创新人才工程Spark Young Innovative Talent Project of General Hospital of Western Theater Command

2022NSFSC14152020JC01242021-XZYG-C222021-XZYG-C212022NSFSC1415

2024

临床肝胆病杂志
吉林大学

临床肝胆病杂志

CSTPCD北大核心
影响因子:1.428
ISSN:1001-5256
年,卷(期):2024.40(2)
  • 17